Showing results (81-90 of 163) with videos related to
Sort By:
Pageof 17
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 21, 2026
The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab TherapyVan Khanh Nguyen, Kosuke Matsui, Hisashi Kosaka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 28, 2025
A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinomaTetsu Tomonari, Shigeo Shimose, Issei Saeki, et al.Plos One|September 25, 2024
Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapyIssei Saeki, Shigeo Shimose, Tetsu Tomonari, et al.Journal of Gastroenterology|March 7, 2025
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept studyTomoko Aoki, Masatoshi Kudo, Naoshi Nishida, et al.Annals of Gastroenterological Surgery|July 3, 2026
Survival Outcomes of Gemcitabine-Cisplatin-S-1 Versus Gemcitabine-Cisplatin in Unresectable Biliary Tract Cancer: A Multicenter Retrospective Study With a Focus on Conversion SurgeryHisashi Kosaka, Masahiko Kinoshita, Satoshi Yasuda, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 11, 2026
Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular CarcinomaKazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 6, 2020
Real-world efficacy and safety of 12-week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infectionYoshinari Takaoka, Kouichi Miura, Naoki Morimoto, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 21, 2025
Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter StudyTakeshi Hatanaka, Shigeo Shimose, Takanori Ito, et al.Cancer Medicine|August 11, 2023
Effect of butyrate-producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumabKazuhiro Nouso, Shohei Shiota, Rio Fujita, et al.Cancer Reports (Hoboken, N.J.)|June 11, 2021
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experienceAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Pageof 17